

Coagulation factor Xa as driver of cardiovascular diseases

Citation for published version (APA):

Posma, J. J. N. (2022). *Coagulation factor Xa as driver of cardiovascular diseases*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20220509jp>

Document status and date:

Published: 01/01/2022

DOI:

[10.26481/dis.20220509jp](https://doi.org/10.26481/dis.20220509jp)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Impact Paragraph

For decades, patients have been prescribed anticoagulants to prevent and treat thrombosis. Anticoagulants inhibit enzymes of the coagulation cascade, and thereby prevent clot formation. Heparin was one of the first anticoagulants introduced already early in the previous century. In the same period, warfarin was introduced and became the number one oral agent to prevent and treat thrombosis. After almost 70 years of warfarin treatment, it became appreciated that warfarin therapy has effects beyond prevention and treatment of thrombosis, including the calcification of large blood vessels. Although warfarin is currently still being used as an anticoagulant, new direct oral anticoagulants (DOACs), such as dabigatran and rivaroxaban (I used the latter anticoagulant extensively in my thesis to study the pleiotropic effects of coagulation), are now the preferred agents in thrombosis management. However, in the past two decades, it became evident that through administration of these anticoagulants, biological and cellular processes beyond coagulation can be modulated. Although long-term effects on biological processes in humans remain largely unknown, preclinical data suggest that DOAC treatment might have protective effects on the cardiovascular system.

Since increasing numbers of patients will be administered DOACs oftentimes lifelong, it is of significant importance to fully elucidate the pleiotropic effects of coagulation proteins and the long-term biological consequence of their inhibition.

In chapter 4 I showed that the anticoagulant drug rivaroxaban, inhibited the development of atherosclerosis, and more importantly promoted regression of highly advanced atherosclerotic lesions. I attempted to further elucidate the biological processes that explain anticoagulant-mediated atheroprotection. In doing so, I revealed that inhibition of the coagulation system by rivaroxaban modulated biology at the genetic level, thereby affecting cellular metabolism. If we can fully understand the pleiotropic actions of inhibition of the coagulation system, we can turn this knowledge into new treatment options for atherosclerosis, without the bleeding risk associated with DOACs. Recent clinical trial data supports the concept of atheroprotection by DOACs: mortality rates significantly decreased in patients with stable coronary artery disease treated with a low dose rivaroxaban (in combination with aspirin) when compared to their control receiving traditional treatment. The studies described in this thesis can help create a stronger foundation for the wider use of a low dose anticoagulant in poly vascular atherosclerotic diseased patients, provided that the benefit risk (bleeding) ratio allows it. More efficient treatment of atherosclerosis will further diminish the burden on society and cost-effectiveness studies demonstrate the potential gain in subsets of patients with atherosclerosis, when treated with the dual pathway inhibition strategy.

Coronary atherosclerosis is the main cause of most myocardial infarctions and combined with stroke, responsible for the majority of deaths in Western

society. The treatment of an acute myocardial infarction is directed towards fast restoration of blood flow to the ischemic heart, termed reperfusion. However, reperfusion is considered a double-edged sword because it further enhances the damage to the infarcted site. Chapter xx describes how inhibition of coagulation by anticoagulants can potentially protect the heart from reperfusion injury, and can thereby provide a better long-term outcome for the patients.

In 2017, treatment of coronary atherosclerotic disease accounted for 22% of the total cardiovascular expenses (and 2.6% of the total healthcare expenses) amounting to 2.3 billion euros in the Netherlands alone. Since no optimal treatment for atherosclerotic disease exists to date, and prevalence rates are expected to rise significantly, expenses can become unsustainable in the next decade. Besides improved patient care, the data from this thesis can aid in decreasing the global economic burden that atherosclerotic disease and myocardial infarction have on society by guiding future treatments strategies.

In conclusion, in the short-term this thesis supports a stronger foundation for wider use of specific anticoagulants and in the long-term it aids in guiding future treatment strategies.